Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
Total Valuation
Crispr Therapeutics AG has a market cap or net worth of $5.35B. The enterprise value is $2.73B.
Market Cap$5.35B
Enterprise Value$2.73B
Share Statistics
Crispr Therapeutics AG has 90,950,424 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding90,950,424
Owned by Insiders2.72%
Owned by Institutions27.65%
Financial Efficiency
Crispr Therapeutics AG’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -21.70%.
Return on Equity (ROE)-0.19
Return on Assets (ROA)-0.16
Return on Invested Capital (ROIC)-21.70%
Return on Capital Employed (ROCE)-0.22
Revenue Per Employee89.06K
Profits Per Employee-931.94K
Employee Count393
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Crispr Therapeutics AG is ―. Crispr Therapeutics AG’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value1.72
Price to FCF―
Price to Operating Cash Flow-15.37
PEG Ratio―
Income Statement
In the last 12 months, Crispr Therapeutics AG had revenue of 35.00M and earned -366.25M in profits. Earnings per share was -4.34.
Revenue35.00M
Gross Profit-75.25M
Operating Income-466.57M
Pretax Income-362.67M
Net Income-366.25M
EBITDA-447.31M
Earnings Per Share (EPS)-4.34
Cash Flow
In the last 12 months, operating cash flow was -324.77M and capital expenditures -796.00K, giving a free cash flow of -325.57M billion.
Operating Cash Flow-324.77M
Free Cash Flow-325.57M
Free Cash Flow per Share-3.58
Dividends & Yields
Crispr Therapeutics AG pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.14
52-Week Price Change22.93%
50-Day Moving Average52.73
200-Day Moving Average44.87
Relative Strength Index (RSI)55.34
Average Volume (3m)3.44M
Important Dates
Crispr Therapeutics AG upcoming earnings date is Oct 29, 2025, TBA (Confirmed).
Last Earnings DateAug 4, 2025
Next Earnings DateOct 29, 2025
Ex-Dividend Date―
Financial Position
Crispr Therapeutics AG as a current ratio of 22.07, with Debt / Equity ratio of 12.59%
Current Ratio22.07
Quick Ratio22.07
Debt to Market Cap<0.01
Net Debt to EBITDA0.17
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Crispr Therapeutics AG has paid 3.59M in taxes.
Income Tax3.59M
Effective Tax Rate>-0.01
Enterprise Valuation
Crispr Therapeutics AG EV to EBITDA ratio is -7.26, with an EV/FCF ratio of -22.44.
EV to Sales92.74
EV to EBITDA-7.26
EV to Free Cash Flow-22.44
EV to Operating Cash Flow-22.73
Balance Sheet
Crispr Therapeutics AG has $1.72B in cash and marketable securities with $215.45M in debt, giving a net cash position of -$1.51B billion.
Cash & Marketable Securities$1.72B
Total Debt$215.45M
Net Cash-$1.51B
Net Cash Per Share-$16.59
Tangible Book Value Per Share$22.90
Margins
Gross margin is -341.43%, with operating margin of -1333.05%, and net profit margin of -1046.43%.
Gross Margin-341.43%
Operating Margin-1333.05%
Pretax Margin-1036.19%
Net Profit Margin-1046.43%
EBITDA Margin-1278.02%
EBIT Margin-1333.05%
Analyst Forecast
The average price target for Crispr Therapeutics AG is $71.94, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$71.94
Price Target Upside22.31% Upside
Analyst ConsensusModerate Buy
Analyst Count21
Revenue Growth Forecast-81.18%
EPS Growth Forecast-69.19%